Top 2 Health Care Stocks That May Plunge In August
Top 2 Health Care Stocks That May Plunge In August
As of Aug 26, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
截至2024年8月26日，醫療保健板塊中的兩隻股票對於那些將動量視爲其交易決策關鍵因素的投資者可能會發出真正的警告。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
RSI是一種動量指標，它將股票在股價上升的日子裏的強度與在股價下跌的日子裏的強度進行比較。與股票價格的走勢相比，它可以讓交易員更好地了解股票在短期內的表現。當RSI高於70時，資產通常被認爲是超買的，據Benzinga Pro稱。
Here's the latest list of major overbought players in this sector.
以下是行業中超買的主要股票列表。
Beigene Ltd (NASDAQ:BGNE)
百濟神州有限公司（NASDAQ：BGNE）
- On Aug. 7, BeiGene posted better-than-expected second-quarter financial results. "This was a tremendous second quarter and an inflection point as BeiGene achieved positive non-GAAP operating income with rapidly increasing global revenues and continued financial discipline. Having now reached this milestone, we will further build on our differentiated, strategic capabilities as a leading, global oncology innovator," said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. The company's stock gained around 19% over the past month and has a 52-week high of $219.64.
- RSI Value: 72.54
- BGNE Price Action: Shares of Beigene fell 0.9% to close at $193.82 on Friday.
- 2024年8月7日，百濟神州發佈了超預期的第二季度財務業績。「這是一個巨大的第二季度，也是百濟神州在不斷增長的全球收入和持續財務紀律方面實現了正面非通用會計原則營業收入的轉折點。達到這個里程碑後，我們將進一步發展我們作爲領先的全球腫瘤創新者的差異化戰略能力，」百濟神州聯合創始人、董事長兼首席執行官John V. Oyler表示。該公司的股價在過去一個月內上漲了約19%，並且達到了52周的最高點$219.64。
- RSI值：72.54
- 百濟神州的股價行情：Beigene股票於週五下跌了0.9%，收盤價爲$193.82。
Halozyme Therapeutics, Inc. (NASDAQ:HALO)
奧洛茲美醫療公司（NASDAQ：HALO）
- On Aug. 6, Halozyme Therapeutics reported better-than-expected second-quarter financial results. "Our strong financial results reflect another quarter of double-digit royalty revenue, EBITDA and earnings growth. We remain on track to deliver on our financial guidance for the full year that was recently raised following the issuance and validation of a new EU patent covering the ENHANZE rHuPH20 product. In the quarter, we also expanded ENHANZE into neurology treatment with Roche's EU and UK approval of Ocrevus SC, while also extending our reach into auto-immune diseases with argenx's FDA approval for VYVGART Hytrulo for the treatment of CIDP," said Dr. Helen Torley, president and chief executive officer of Halozyme. The company's stock gained around 12% over the past month and has a 52-week high of $62.86.
- RSI Value: 76.12
- HALO Price Action: Shares of Halozyme Therapeutics gained 1.8% to close at $62.72 on Friday.
- 8月6日，奧洛茲美醫療發佈了超出預期的第二季度財務業績報告。我們強勁的財務業績體現了雙位數的版稅收入、EBITDA和盈利增長。我們將按照最近因發佈和驗證涵蓋ENHANZE rHuPH20產品的新歐盟專利而提高的全年財務指引繼續推進。在這個季度，我們還通過羅氏公司在歐盟和英國批准的Ocrevus SC擴展了ENHANZE，同時還通過argenx公司獲得了VYVGARt Hytrulo用於CIDP治療的FDA批准，進入了自身免疫性疾病領域。奧洛茲美醫療總裁兼首席執行官Helen Torley博士表示:"我們公司股價在過去一個月上漲了約12%，並且股價創下了62.86美元的52周高點。"
- RSI數值：76.12
- HALO價格走勢：奧洛茲美醫療股價週五上漲1.8%，收於62.72美元。
Read More:
閱讀更多：
- Jim Cramer Praises L3Harris Technologies, Says Intel Is 'Getting Whacked' By AMD: 'I Much Prefer...'
- 吉姆·克雷默讚揚L3Harris Technologies，並表示英特爾（Intel）正受到AMD的打擊：'我更喜歡……'
